Recent progress in tumour vaccine development

被引：5

作者：

Le Poole, IC ^{[1
]}

Bommiasamy, H

Kast, WM

机构：

[1] Loyola Univ, Canc Immunol Program, Cardinal Barnardin Canc Ctr, Chicago, IL 60611 USA

[2] Loyola Univ, Dept Pathol, Chicago, IL 60611 USA

[3] Loyola Univ, Dept Microbiol & Immunol, Chicago, IL USA

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2003年 / 12卷 / 06期

关键词：

adjuvants antibodies; antigens; dendritic cells; immune monitoring; immunotherapy; T cells; tumour vaccine;

D O I：

10.1517/13543784.12.6.971

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Immunotherapy offers an exciting opportunity to treat human cancer. Analysis of tumour-associated antigens is progressing. Assisted by animal models, such knowledge can be used to design tumour vaccines. By including adjuvants to increase immunogenicity several tumours previously thought to be non-immunogenic are now considered targets for tumour vaccines. Newly acquired knowledge regarding dendritic cell physiology is incorporated in newly designed vaccines that are currently in Phase I and II trials. Such assessment provides the overall conclusion that tumour vaccines are safe and deserve a more prominent place in the sequel of treatments for human cancer.

引用

页码：971 / 981

页数：11

共 114 条

[1]

Aarts WM, 2002, CANCER RES, V62, P5770

[2] Intermediate- and high-risk melanoma. [J].

Agarwala S.S. .

Current Treatment Options in Oncology, 2002, 3 (3) :205-217

[3] Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma [J].

Antonia, SJ ;

Seigne, J ;

Diaz, J ;

Muro-Cacho, C ;

Extermann, M ;

Farmelo, MJ ;

Friberg, M ;

Alsarraj, M ;

Mahany, JJ ;

Pow-Sang, J ;

Cantor, A ;

Janssen, W .

JOURNAL OF UROLOGY, 2002, 167 (05) :1995-2000

[4]

Armstrong Todd D, 2002, Surg Oncol Clin N Am, V11, P681, DOI 10.1016/S1055-3207(02)00020-0

[5]

Baars A, 2002, HEPATO-GASTROENTEROL, V49, P691

[6] Toxicity of a GM3 cancer vaccine in Macaca fascicularis monkey:: a 12-month study [J].

Bada, A ;

Parada, AC ;

Arieaga, M ;

Martínez, J ;

León, A ;

Santana, E ;

Hernández, O ;

Orphee, R ;

González, A ;

Mesa, C ;

González, C ;

Montero, E ;

Fernández, LE .

HUMAN & EXPERIMENTAL TOXICOLOGY, 2002, 21 (05) :263-267

[7] The long arm of the immune system [J].

Banchereau, J .

SCIENTIFIC AMERICAN, 2002, 287 (05) :52-59

[8] Amino acid modifications in the wild type sequence p53 232-240 overcome the poor immunogenicity of this self tumour epitope [J].

Baratin, M ;

Kayibanda, M ;

Ziol, M ;

Romieu, R ;

Briand, JP ;

Guillet, JG ;

Viguier, M .

JOURNAL OF PEPTIDE SCIENCE, 2002, 8 (07) :327-334

[9] Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes:: Clinical and immunologic findings [J].

Belli, F ;

Testori, A ;

Rivoltini, L ;

Maio, M ;

Andreola, G ;

Sertoli, MR ;

Gallino, G ;

Piris, A ;

Cattelan, A ;

Lazzari, I ;

Carrabba, M ;

Scita, G ;

Santantonio, C ;

Pilla, L ;

Tragni, G ;

Lombardo, C ;

Arienti, F ;

Marchianò, A ;

Queirolo, P ;

Bertolini, F ;

Cova, A ;

Lamaj, E ;

Ascani, L ;

Camerini, R ;

Corsi, M ;

Cascinelli, N ;

Lewis, JJ ;

Srivastava, P ;

Parmiani, G .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (20) :4169-4180

[10]

Benvenuti F., 2002, Current Gene Therapy, V2, P235, DOI 10.2174/1566523024605654

← 1 2 3 4 5 6 7 8 9 10 →